Properties of adaptive clinical trial signature design in the presence of gene and gene-treatment interaction
From MaRDI portal
Publication:3133090
Recommendations
Cited in
(14)- Direct meshless local Petrov-Galerkin (DMLPG) method for time-fractional fourth-order reaction-diffusion problem on complex domains
- DMLPG method for specifying a control function in two-dimensional parabolic inverse PDEs
- Direct meshless local Petrov-Galerkin method for the two-dimensional Klein-Gordon equation
- Numerical investigation of the magnetic properties and behavior of electrically conducting fluids via the local weak form method
- A study of nonlinear systems arising in the physics of liquid crystals, using MLPG and DMLPG methods
- Investigation of generalized Couette hydromagnetic flow of two-step exothermic chemical reaction in a channel via the direct meshless local Petrov-Galerkin method
- Direct meshless local Petrov-Galerkin method to investigate anisotropic potential and plane elastostatic equations of anisotropic functionally graded materials problems
- Remediation of contaminated groundwater by meshless local weak forms
- Numerical study of the variable-order time-fractional mobile/immobile advection-diffusion equation using direct meshless local Petrov-Galerkin methods
- DMLPG method for numerical simulation of soliton collisions in multi-dimensional coupled damped nonlinear Schrödinger system which arises from Bose-Einstein condensates
- Interpolating meshless local Petrov-Galerkin method for steady state heat conduction problem
- A direct meshless local collocation method for solving stochastic Cahn-Hilliard-Cook and stochastic Swift-Hohenberg equations
- The meshless local Petrov-Galerkin method based on moving Taylor polynomial approximation to investigate unsteady diffusion-convection problems of anisotropic functionally graded materials related to incompressible flow
- Direct meshless local Petrov-Galerkin (DMLPG) method for 2D complex Ginzburg-Landau equation
This page was built for publication: Properties of adaptive clinical trial signature design in the presence of gene and gene-treatment interaction
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3133090)